Antiviral Efficacy of Pralatrexate against SARS-CoV-2
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Bae, Joon-Yong | - |
dc.contributor.author | Lee, Gee Eun | - |
dc.contributor.author | Park, Heedo | - |
dc.contributor.author | Cho, Juyoung | - |
dc.contributor.author | Kim, Jeonghun | - |
dc.contributor.author | Lee, Jungmin | - |
dc.contributor.author | Kim, Kisoon | - |
dc.contributor.author | Kim, Jin Il | - |
dc.contributor.author | Park, Man-Seong | - |
dc.date.accessioned | 2021-11-20T20:40:30Z | - |
dc.date.available | 2021-11-20T20:40:30Z | - |
dc.date.created | 2021-08-30 | - |
dc.date.issued | 2021-05 | - |
dc.identifier.issn | 1976-9148 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/128154 | - |
dc.description.abstract | Novel coronavirus (SARS-CoV-2) has caused more than 100 million confirmed cases of human infectious disease (COVID-19) since December 2019 to paralyze our global community. However, only limited access has been allowed to COVID-19 vaccines and antiviral treatment options. Here, we report the efficacy of the anticancer drug pralatrexate against SARS-CoV-2. In Vero and human lung epithelial Calu-3 cells, pralatrexate reduced viral RNA copies of SARS-CoV-2 without detectable cytotoxicity, and viral replication was successfully inhibited in a dose-dependent manner. In a time-to-addition assay, pralatrexate treatment at almost half a day after infection also exhibited inhibitory effects on the replication of SARS-CoV-2 in Calu-3 cells. Taken together, these results suggest the potential of pralatrexate as a drug repurposing COVID-19 remedy. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | KOREAN SOC APPLIED PHARMACOLOGY | - |
dc.title | Antiviral Efficacy of Pralatrexate against SARS-CoV-2 | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, Kisoon | - |
dc.contributor.affiliatedAuthor | Kim, Jin Il | - |
dc.contributor.affiliatedAuthor | Park, Man-Seong | - |
dc.identifier.doi | 10.4062/biomolther.2021.032 | - |
dc.identifier.scopusid | 2-s2.0-85106509753 | - |
dc.identifier.wosid | 000652473600003 | - |
dc.identifier.bibliographicCitation | BIOMOLECULES & THERAPEUTICS, v.29, no.2, pp.268 - 272 | - |
dc.relation.isPartOf | BIOMOLECULES & THERAPEUTICS | - |
dc.citation.title | BIOMOLECULES & THERAPEUTICS | - |
dc.citation.volume | 29 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 268 | - |
dc.citation.endPage | 272 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART002708636 | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | Biochemistry & Molecular Biology | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Biochemistry & Molecular Biology | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.subject.keywordAuthor | Antiviral | - |
dc.subject.keywordAuthor | COVID-19 | - |
dc.subject.keywordAuthor | Drug repurposing | - |
dc.subject.keywordAuthor | SARS-CoV-2 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.